Elevated LDL cholesterol is a major contributor to heart disease globally. Statins have served as the primary treatment for decades. Subsequently, a new class of injectable drugs, PCSK9 inhibitors, significantly reduced LDL cholesterol in patients inadequately managed by statins. Although effective, these therapies are expensive, require frequent administration, and are inaccessible to much of the global population.
A 2025 study published in Biochemical Pharmacology by researchers at the University of Barcelona and Oregon Health & Science University reports a novel approach: a single injection of a synthetic DNA molecule can silence the gene responsible for PCSK9 production, thereby reducing both PCSK9 and total cholesterol levels by nearly half, with no detectable toxicity.
This technology, termed Polypurine Reverse Hoogsteen hairpins (PPRHs), may represent one of the most promising and cost-efficient advances in cardiovascular gene therapy in recent years.
The Cholesterol Problem That Statins Can’t Fully Solve
Understanding the significance of this discovery requires an explanation of PCSK9’s biological function.
Liver cells possess LDL receptors, which are proteins on the cell surface that capture LDL cholesterol from the bloodstream for recycling. A higher number of LDL receptors correlates with lower blood cholesterol levels. PCSK9, a protein secreted by the liver, antagonizes this process by binding to LDL receptors and targeting them for degradation, thereby reducing the liver’s capacity to clear cholesterol from the blood.
Individuals with elevated PCSK9 activity, whether due to genetic or other factors, experience increased accumulation of LDL cholesterol in the bloodstream. This accelerates the formation of arterial plaques, which can lead to heart attacks and strokes. In its most severe form, familial hypercholesterolemia, the condition affects millions worldwide and substantially increases lifetime cardiovascular risk.
Current PCSK9 inhibitors, including the monoclonal antibodies evolocumab and alirocumab, as well as the siRNA-based drug Inclisiran, function by blocking circulating PCSK9 protein or reducing its production. While effective, monoclonal antibodies require administration every two to four weeks or monthly and cost between $5,000 and $14,000 per year in the United States. Inclisiran, although administered only twice annually, also incurs substantial costs and necessitates complex chemical modifications typical of RNA-based drugs to ensure clinical stability.
A counterintuitive issue with monoclonal antibodies is that, by targeting circulating PCSK9 rather than its hepatic production, they can cause PCSK9 levels to increase significantly after injection, sometimes reaching ten to fifteen times baseline levels, even as LDL cholesterol decreases. The long-term physiological consequences of this elevation remain unclear.
What PPRHs Are and How They Work
Polypurine Reverse Hoogsteen hairpins are small, unmodified DNA molecules that fold into a hairpin structure due to their self-complementary sequences. Unlike RNA-based therapies or antibodies, PPRHs are composed solely of DNA.
The primary mechanism involves the PPRH hairpin locating a specific sequence within the target gene’s DNA and binding to it via a triplex bond, effectively inserting itself as a third strand alongside the double helix. This interaction physically disrupts gene transcription, resulting in reduced mRNA production and, consequently, decreased synthesis of the encoded protein, such as PCSK9.
This approach differs fundamentally from monoclonal antibodies, which act downstream by neutralizing PCSK9 after its production and secretion, and from CRISPR gene editing, which physically cleaves DNA. PPRHs function upstream at the gene level, suppressing transcription without permanently altering the DNA sequence. As PPRHs naturally degrade over time, gene function gradually returns to baseline, rendering the effect reversible and providing a notable safety advantage.
PPRHs, composed of unmodified DNA rather than chemically modified RNA, are considerably simpler and less costly to synthesize compared to current nucleic acid therapies. The manufacturing complexity and expense associated with drugs such as Inclisiran present significant barriers to global access, whereas PPRHs are designed to circumvent much of this complexity.
What the Study Found: Lab Cells and Living Mice
The researchers developed two PPRH molecules targeting distinct regions of the PCSK9 gene: one targeting exon 9 (HpE9) and another targeting exon 12 (HpE12). Initial testing was conducted in HepG2 cells, a human liver cell line commonly utilized in pharmaceutical research.
The cell culture results were notable. Within 24 hours of transfection, HpE9 reduced PCSK9 mRNA levels by 63%, while HpE12 achieved a 74% reduction. At the protein level, intracellular PCSK9 decreased by up to 96% at 48 hours. Importantly, PCSK9 secretion into the culture medium also declined substantially, confirming reduced production and release of functional protein.
As PCSK9 protein levels decreased, LDL receptor levels increased correspondingly. The protein responsible for clearing LDL cholesterol from the bloodstream rose by up to 253% at the protein level following 48 hours of HpE12 treatment. This outcome aligns with the therapeutic objective: reducing PCSK9 to restore LDL receptor function and lower cholesterol. The cell culture data confirmed the intended pathway.
Subsequently, the researchers employed a mouse model. Transgenic mice engineered to overexpress human PCSK9 received a single intraperitoneal injection of HpE12, complexed with the delivery polymer jetPEI to facilitate DNA uptake by liver cells. Control groups were administered either a scrambled (non-specific) PPRH sequence or a PPRH targeting an unrelated gene, neither of which would be expected to influence PCSK9 expression.
By the second day post-injection, plasma PCSK9 levels in the HpE12 group had decreased by approximately 48% from baseline, and total serum cholesterol declined by 47% by the third day. Both measures returned toward baseline by day fifteen, consistent with the transient nature of PPRH-mediated gene silencing as the DNA hairpin degrades and gene expression resumes. Neither control group exhibited significant changes in PCSK9 or cholesterol levels.
Safety: No Toxicity Detected
For any novel therapeutic technology, safety is as critical as efficacy. The researchers rigorously assessed PPRH toxicity in wild-type mice that received two injections over a ten-day period.
Body weight remained stable throughout the experiment. Liver enzyme levels ALT and AST, the standard markers of liver damage, showed no significant changes between the PPRH-treated mice and controls. Inflammatory markers TNF-alpha and C-reactive protein (CRP), which would signal an immune response, were also unchanged. No sex-dependent differences in toxicity were observed.
This favorable safety profile is consistent with previous findings from cancer research, in which PPRHs have not been associated with off-target gene effects or innate immune activation that can complicate RNA-based therapies. As double-stranded DNA molecules, PPRHs elicit less immune response than RNA-based agents. Furthermore, their mechanism of triplex formation, rather than DNA cleavage as in CRISPR, avoids the risk of chromosomal rearrangements, a significant safety concern in gene-editing approaches.
Where This Technology Could Go
The researchers emphasize that this is a proof-of-concept study and represents the first application of PPRH technology to a metabolic disease target. Several critical steps remain before clinical translation can be achieved.
An immediate priority is optimizing the delivery system. The current study utilized jetPEI, a cationic polymer that, although effective, lacks liver specificity. Future development will likely involve N-acetylgalactosamine (GalNAc), a sugar molecule that selectively targets liver cells and is already employed in Inclisiran delivery. GalNAc-conjugated PPRHs could substantially improve biodistribution, prolong hepatic persistence, and potentially allow for lower effective doses.
Extending the duration of the effect is also necessary. The current 15-day window of PCSK9 suppression is promising for proof-of-concept but insufficient for clinical application. Optimized delivery and dosing strategies may significantly prolong the therapeutic effect.
The researchers also highlight PCSK9’s expanding relevance beyond cholesterol regulation. This protein has been implicated in inflammatory processes, liver disease, viral infections, and certain cancer pathways. If PPRH technology can be robustly developed for PCSK9, the platform could potentially be adapted for a broad range of disease targets, positioning PPRHs as a versatile gene-silencing technology rather than a single-disease solution.
The Bottom Line
Heart disease is the leading cause of mortality worldwide, and elevated LDL cholesterol is among its most modifiable risk factors. Although current PCSK9 inhibitors are effective, they remain expensive, complex to manufacture, and inaccessible to most individuals in need.
This study demonstrates that a simple, unmodified DNA hairpin molecule can silence the gene central to LDL cholesterol dysregulation, reduce cholesterol levels by nearly half with a single injection, and do so without detectable toxicity. The approach does not involve DNA cleavage, does not require costly chemical modifications, and can, in principle, be manufactured at a fraction of the cost of current biologics.
Although this technology is in the early stages of development, the supporting evidence is robust, the mechanism is well-established, and the clinical need is urgent. For millions of patients worldwide who remain undertreated for high cholesterol due to cost, access, or side effect concerns, research of this nature represents the type of innovation that could ultimately improve outcomes on a global scale.
References
López-Aguilar, E., Pacheco-Velázquez, S.C., Busquets, M.-A., Hay, J., Mueller, P.A., Fazio, S., Ciudad, C.J., Noé, V., & Pamir, N. (2025). Inhibition of PCSK9 with polypurine reverse Hoogsteen hairpins: A novel gene therapy approach. Biochemical Pharmacology, 238, 116976. https://doi.org/10.1016/j.bcp.2025.116976